Free tool
FAERS Monitor: Lamisil At
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021958 or its brand name (Lamisil At, Terbinafine). Reports on generic versions are filed under their own applications.
Reports
1,412
Serious
890
63% of reports
Hospitalization
349
Death reported
54
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective121
- pruritus87
- rash82
- nausea75
- pain67
- fatigue66
- dyspnoea59
- off label use59
- diarrhoea53
- ageusia51
- headache50
- weight decreased50
- condition aggravated46
- cough45
- erythema44
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 30 |
| 2008 | 33 |
| 2009 | 20 |
| 2010 | 30 |
| 2011 | 26 |
| 2012 | 41 |
| 2013 | 16 |
| 2014 | 17 |
| 2015 | 58 |
| 2016 | 46 |
| 2017 | 55 |
| 2018 | 63 |
| 2019 | 80 |
| 2020 | 75 |
| 2021 | 86 |
| 2022 | 155 |
| 2023 | 154 |
| 2024 | 173 |
| 2025 | 160 |
| 2026 | 90 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,747 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ageusiaSignal | 51 | 30.5 | 23.3 | 1,425 |
| pruritusSignal | 87 | 3.4 | 2.8 | 145 |
| erythemaSignal | 44 | 3.2 | 2.4 | 65 |
| rashSignal | 82 | 2.8 | 2.3 | 95 |
| weight decreasedSignal | 50 | 2.7 | 2.0 | 51 |
| coughSignal | 45 | 2.4 | 1.8 | 35 |
| condition aggravatedSignal | 46 | 2.3 | 1.7 | 31 |
| pain | 67 | 1.6 | 1.3 | 16 |
| dyspnoea | 59 | 1.6 | 1.2 | 11 |
| nausea | 75 | 1.4 | 1.1 | 9 |
| drug ineffective | 121 | 1.4 | 1.2 | 12 |
| fatigue | 66 | 1.3 | 1.0 | 3 |
| diarrhoea | 53 | 1.2 | 0.9 | 2 |
| headache | 50 | 1.2 | 0.9 | 1 |
| off label use | 59 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.